Left ventricular (LV) myocardial structure and function differ in heart failure (HF) with normal (N) and reduced (R) LV ejection fraction (EF). This difference could underlie an unequal outcome of trials with b-blockers in heart failure with normal LVEF (HFNEF) and heart failure with reduced LVEF (HFREF) with mixed results observed in HFNEF and positive results in HFREF. To investigate whether b-blockers have distinct myocardial effects in HFNEF and HFREF, myocardial structure, cardiomyocyte function, and myocardial protein composition were compared in HFNEF and HFREF patients without or with b-blockers.
Introduction
Over the past two decades, it became evident that more than 50% of all heart failure (HF) patients suffer of HF with normal left ventricular (LV) ejection fraction (EF). 1 In heart failure with normal LVEF (HFNEF) and in heart failure with reduced LVEF (HFREF), LV structure adapts differently with concentric LV remodelling in HFNEF and eccentric LV remodelling in HFREF. 2 -4 Corresponding differences were observed at the myocardial ultrastructural level with prominent cardiomyocyte hypertrophy in HFNEF and low myofibrillar density in HFREF. 4 When cardiomyocytes were isolated from LV myocardium, cardiomyocyte resting tension (F passive ) was also higher in HFNEF than in HFREF. 4 -6 These structural and functional differences between LV myocardium in HFNEF and HFREF could underlie the unequal outcome of trials using b-blockers, angiotensin converting enzyme inhibitors (ACE-I), or angiotensin II receptor blockers (ARB) which usually yielded positive results in HFREF and mixed results in HFNEF. 7, 8 In line with this unequal outcome of trials, prognosis of HFREF patients improved over the last two decennia, whereas no such trend was observed in HFNEF patients. 1 Large clinical trials have convincingly shown that b-blocker therapy reduces mortality and improves LV function in HFREF patients. 9 -11 In HFNEF patients, favourable effects of b-blocker therapy on mortality and LV function have not been convincingly demonstrated. After hospital discharge, HFNEF patients had improved survival when using b-blockers 12 and in a communitybased registry, carvedilol use was accompanied by similar 1 year mortality in HFNEF and HFREF patients but less reduction in hospitalizations in HFNEF patients. 13 In the SWEDIC trial, carvedilol had no effect on mortality or hospitalizations, but ameliorated E/A ratio of HFNEF patients. 14 In a similar study, however, 6 months of atenolol use had no effect on diastolic LV function of HFNEF patients with unchanged pulmonary capillary wedge pressure. 15 Because of these inconsistent results, the use of b-blockers in HFNEF patients is further evaluated in clinical trials, such as the Japanese DHF study. 16 To investigate whether HF therapy has indeed disparate effects on LV myocardial structure and function in HFNEF and HFREF, the present study compared LV myocardial structure, function, and protein composition in HFNEF and HFREF patients with and without b-blockers. The current widespread use of ACE-I precluded a similar comparison in patients with and without ACE-I. Endomyocardial biopsies procured in the four patient groups were used for: (i) histomorphometry of light and electron microscopic images to determine cardiomyocyte diameter (MyD), collagen volume fraction (CVF), and myofibrillar density; (ii) isolation of single cardiomyocytes to measure active force (F active ), resting force (F passive ), and Ca 2þ -sensitivity (pCa 50 ), and (iii) protein analysis to assess phosphorylation of myofilamentary proteins and the expression of proteins involved in b-adrenergic signalling and in Ca 2þ -handling.
Methods
The Supplementary methods section provides a detailed description of the methodology used for quantitative histomorphometry, force measurements in isolated cardiomyocytes, and protein analysis.
Patients
All patients included in the study (n ¼ 71) had been hospitalized for worsening HF and were referred for cardiac catheterization and LV biopsy procurement because of suspicion of infiltrative or inflammatory myocardial disease. No patient had significant (.50%) coronary artery stenoses, a history of myocardial infarction, percutaneous coronary intervention, or coronary bypass surgery. Histological analysis of the biopsies showed no myocardial infiltration or inflammation. The local ethics committee approved the study protocol of Vrij Universiteit medical center (Vumc). Written informed consent was obtained from all patients, and there were no complications related to catheterization or biopsy procurement. Patients were classified as HFREF if LVEF,40% and as HFNEF if LVEF.50% and LV end-diastolic pressure (LVEDP) .16 mmHg. 17 Patients with a LVEF.40% but ,50% were not included.
The patients had either new-onset HF or acute decompensation superimposed on chronic HF. Sixty-four percent of patients had new-onset HF and 36% had acute decompensation superimposed on chronic HF. Patients were studied after medical compensation.
Data analysis
Values are given as mean + SEM of the observations in each patient group. Data of the b2 HFNEF , bþ HFNEF , b2 HFREF , and bþ HFREF groups were compared by two-factor ANOVA testing for b-blocker use, HFNEF/HFREF status, and their interaction ( Tables 1 and 2 ). Subsequent comparisons (b2 HFREF vs. bþ HFREF and b2 HFNEF vs. bþ HFNEF ) were performed with a Bonferroni adjusted t-test. The analyses were performed in GraphPad Prism version 4 and SPSS 12.0.
Results

Clinical and haemodynamic characteristics
Clinical, haemodynamic, and echocardiographic data are presented in Table 1 . Patients on b-blocker therapy had lower heart rate and LVEDP in both HFNEF and HFREF groups. Heart failure with normal LVEF patients were older and more frequently suffered of arterial hypertension with a concomitant higher use of calcium channel and ARB. Heart failure with normal LVEF patients also had higher LV peak systolic pressure, LVEDP, LVEF, LVdP/ dt max , LVdP/dt min , LV wall thickness, LV mass index/LV enddiastolic volume index (LVMI/LVEDVI) ratio, and smaller LVEDVI.
Histomorphometry
Histomorphometric data are summarized in Table 2 and Figure 1 .
Myocardial CVF was significantly lower in HFNEF than in HFREF (P , 0.0001) and only in HFNEF was b-blocker therapy associated with lower myocardial CVF (P ¼ 0.0007). Myocyte diameter was significantly higher in HFNEF than in HFREF (P , 0.0001) and only in HFNEF was b-blocker therapy associated with reduced MyD (P , 0.0001). Myofibrillar density was also higher in HFNEF than HFREF (P , 0.0001), but was unrelated to b-blocker therapy.
Force measurements in isolated cardiomyocytes
Single cardiomyocytes were attached between a force transducer and a motor (Figure 2A and B) and their sarcomere length was adjusted to 2.2 mm. Force measurements are summarized in Table 2 and Figure 2C . F active and pCa 50 were similar in HFNEF and HFREF, but F passive was higher in HFNEF (P ¼ 0.0006). In both HFNEF and HFREF patients, b-blocker therapy resulted in a significant increase in F active (P ¼ 0.01) and pCa 50 (P ¼ 0.008). Only in HFNEF patients did b-blocker therapy raise F passive (P ¼ 0.03). After protein kinase A (PKA) administration to the cardiomyocytes, F active was comparable in all four patient groups. After PKA, F passive fell in all four groups but remained significantly higher in HFNEF patients with b-blockers (P ¼ 0.001) ( Figure 3A) . pCa 50 followed a trend similar to F passive by decreasing in all four groups and by remaining higher in HFNEF patients with b-blockers (P ¼ 0.007) ( Figure 3B ). Hence, in vivo b-blocker therapy was associated with multiple in vitro changes in baseline and PKA-stimulated contractile function of isolated cardiomyocytes, which differed between HFNEF and HFREF groups.
Protein analysis
Myofilament protein phosphorylation To explore changes in myofilamentary protein phosphorylation related to b-blocker therapy, Pro-Q Diamond-stained gels of biopsies were obtained as shown in Figure 4A . Phosphorylation status of myofilamentary proteins did not differ between HFNEF and HFREF groups. b-blocker therapy was associated with lower phosphorylation of troponin I (TnI) and of myosin-binding protein C (MyBP-C) in both HFNEF and HFREF patients ( Figure 4B ) and had no effect on phosphorylation status of other myofilamentary proteins ( Table 2) . Effect of b-blocker therapy on phosphorylation status of desmin differed with opposite changes in HFNEF and HFREF patients (P , 0.05).
b-Adrenergic signalling proteins
Expression levels of proteins involved in b-adrenergic receptor signalling were determined by western immunoblotting ( Table 2) . Expression of b 1 AR, GRK2, and GRK5 was higher in HFREF than in HFNEF, but unaffected by b-blocker therapy. b-Blocker therapy was related to downregulated expression of b 2 AR in HFREF and HFNEF. Effects of b-blocker therapy on expression of Gs and Gi differed in HFNEF and HFREF with Gs downregulated in HFNEF and Gi downregulated in HFREF.
Calcium-handling proteins
Expression levels of sarcoplasmic reticulum (SR) Ca2þ-ATPase (SERCA2a) and phospholamban (PLB) were determined by western immunoblotting ( Table 2) . No differences related to HFNEF-HFREF status or to b-blocker therapy were observed. The ratio of SERCA2a/PLB was higher in HFREF (1.0 + 0.2) than in HFNEF (0.5 + 0.08; P ¼ 0.02) and unaffected by b-blocker therapy in both groups.
Discussion
In endomyocardial biopsies of HFNEF or HFREF patients, b-blocker therapy was associated not only with structural and functional myocardial changes shared by both HF phenotypes, but also by changes unique to each HF phenotype. and MyBP-C, and lower expression of b 2 AR. Effects of b-blocker therapy unique to HFNEF were reduced interstitial fibrosis, regression of cardiomyocyte hypertrophy, elevated F passive before and after PKA, elevated pCa 50 after PKA, and reduced expression of Gs. An effect of b-blocker therapy unique to HFREF was the reduced expression of Gi. Effect of b-blocker therapy on phosphorylation status of desmin also differed between HFNEF and HFREF with opposite changes in both groups.
Myocardial effects of b-blocker therapy present in both heart failure with normal left ventricular ejection fraction and heart failure with reduced left ventricular ejection fraction PKA, protein kinase A; pTnI, phosphorylated troponin I; pTnT, phosphorylated troponin T; pMyBP-C, phosphorylated myosin-binding protein C; pDesmin, phosphorylated desmin; pMLC-2, phosphorylated myosin light chain-2; b 1 AR, beta1-adrenergic receptor; b 2 AR, beta2-adrenergic receptor; GRK2, G-coupled receptor kinase 2; GRK5, G-coupled receptor kinase 5; Gs, G-stimulatory; Gi, G-inhibitory; SERCA2a, sarcoplasmic reticulum (SR) Ca2þ-ATPase (SERCA2a); PLB, phospholamban. concentration is outside the physiological range, higher F active also reflects an increased cardiomyocyte force generating capacity. The present study observed reduced phosphorylation of MyBP-C in both b-blocker therapy groups. This reduction could relate to the lack of preload dependence of LV dP/dt max , which was Beta-blockers in HFNEF and HFREF evident in both b-blocker therapy groups from the unchanged LV dP/dt max despite lower LVEDP. Preload dependence of early LV pressure rise was recently demonstrated in transgenic mice to derive from phosphorylation of MyBP-C. 19, 20 Reduced phosphorylation of MyBP-C during chronic b-blocker therapy could have resulted both from lower PKA activity and from lower activity of Ca 2þ -calmodulin-dependent kinase (CaM-kinase). CaM-kinase can phosphorylate MyBP-C and its activity is also enhanced by b-adrenergic receptor stimulation. 21 -23 In longitudinal studies performing serial haemodynamic investigations in HFREF patients, before and during chronic b-blocker therapy, improved myocardial contractile performance was evident from higher LVEF and lower LV filling pressures. 24 -28 The present study confirmed lower LVEDP with b-blocker therapy in both HFNEF and HFREF groups. The enhanced pCa 50 and increased F active observed in isolated cardiomyocytes of b-blocker treated patients suggested improved cardiomyocyte contractile performance to contribute to the in vivo lowering of LVEDP induced by b-blocker therapy. The enhanced pCa 50 and increased F active could also have contributed to the lower LVEDP in the HFNEF patient group despite the increased F passive of the bþ HFNEF cardiomyocytes.
In sequential right ventricular biopsies of patients with dilated cardiomyopathy, cardiac b-receptor density increased during metoprolol 25 and carvedilol therapy. 27 A subsequent study using explanted hearts corroborated these findings and also observed restoration of cardiac b-receptor density by carvedilol treatment. 29 In the present study, which used LV biopsies, chronic b-blocker therapy had no effect on b 1 AR expression but downregulated b 2 AR expression. The present study, however, did not look at bAR density in membrane fractions but at bAR protein expression in homogenates. Downregulation of b 2 AR is beneficial for cardiac contractile performance because of less negative inotropy resulting from coupling of b 2 AR to Gi proteins. 30 Coupling of b 2 AR to Gi was recently also suggested to cause the apical LV dysfunction in patients with Takotsubo cardiomyopathy. 31 Previous investigations 27 demonstrated that b-blocker therapy induced LV functional improvement in HFREF patients by altering expression of genes responsible for cardiomyocyte contractility. The present study also related LV functional amelioration during b-blocker therapy to improved cardiomyocyte contractility and did so in both HFREF and HFNEF patient groups. In contrast to previous studies, contractility of single cardiomyocytes was directly assessed and its improvement was evident from both higher pCa 50 and F active and linked to lower phosphorylation of TnI and MyBP-C and to reduced expression of b 2 AR.
Myocardial effects of b-blocker therapy unique to heart failure with normal left ventricular ejection fraction
Only in HFNEF patients, CVF was lower in the group with b-blockers. The absence of an effect of b-blockers on CVF in HFREF patients supports previous studies, which identified high myocardial fibrosis as an important predictor for poor outcome on b-blocker therapy in HFREF. 32, 33 The lower CVF observed in bþ HFNEF patients was paralleled by a reduction of cardiomyocyte hypertrophy evident from lower MyD. In spontaneously hypertensive rats, the b-blocker bisoprolol did not reverse cardiomyocyte hypertrophy in contrast to the ACE-I perindopril. 34 This study suggests that reduced renin-angiotensin system activity could possibly be involved in the observed regression of cardiomyocyte hypertrophy in the bþ HFNEF patients. Both the reduced cardiomyocytes diameter (MyD) and lower CVF could have contributed to the lower LVEDP in HFNEF patients treated with b-blockers. In our previous study, 5 we observed that both passive cardiomyocyte stiffness and CVF contribute to increased LVEDP. Hence, although F passive was increased in the bþ HFNEF , the lower LVEDP in this patient group probably resulted from less cardiomyocyte hypertrophy and lower CVF. Previous longitudinal studies showed LV mass to decrease in both HFNEF 15 and HFREF patients 24, 26, 28 as a result of b-blocker therapy. Because of smaller LVEDVI, reduction of LV mass resulted in unaltered relative wall thickness in HFREF patients. In HFNEF patients, LV volumes remained unchanged and reduction of LV mass resulted in decreased relative wall thickness. The present study also observed unchanged LVMI/LVEDVI ratio in the HFREF group and a trend for reduced LVMI/LVEDVI ratio in the HFNEF group. The reversal of LV remodelling with b-blocker therapy therefore parallels the regression of cardiomyocyte hypertrophy observed in the present study with unchanged MyD in HFREF and decreased MyD in HFNEF. Skinned cardiomyocytes isolated from biopsies of HFNEF patients have an elevated F passive , which was higher than F passive of HFREF cardiomyocytes 4 or of normal cells. 5 In vitro administration of PKA corrected the high F passive of HFNEF cardiomyocytes, which was therefore attributed to phosphorylatable myofilamentary proteins. 4 Within the HFNEF patient group, the present study observed higher F passive in bþ HFNEF patients than in b2 HFNEF patients. After in vitro administration of PKA, F passive was still higher in bþ HFNEF patients. This finding suggests the effect of b-blocker therapy on cardiomyocyte F passive in HFNEF relates not only to hypophosphorylation but also to structural or other posttranslational modifications of myofilamentary proteins. The persistent elevation of pCa 50 after PKA observed in bþ HFNEF cardiomyocytes also supports b-blocker therapy to induce additional modifications of myofilamentary proteins. Heart failure with reduced LVEF is usually associated with reduced b 1 AR density and translocation of GRK2 to the plasma membrane. These changes in b-adrenergic signalling were not observed in a recently published HFNEF rat model. 35 Although the present study did not look at bAR density in membrane fractions but at bAR protein expression in homogenates, it found important differences in the expression of b 1 AR and GRK2 proteins between patient groups with higher myocardial expression of both proteins in HFREF than in HFNEF irrespective of the use of b-blockers. This unequal expression of b-adrenergic signalling proteins in both HF phenotypes could explain changes in other components of the b-adrenergic system by b-blocker therapy unique for each HF phenotype. Of the different components of the b-adrenergic system, Gs protein was significantly lower in HFNEF patients with b-blockers. Downregulation of b 2 AR-Gs signalling could be beneficial as it would favour b 2 AR-Gi signalling, which is known to exert antiapoptotic effects. 36 Because of normal contractile LV function, potential negative inotropic effects resulting from increased b 2 AR-Gi signalling are less important for HFNEF patients.
Myocardial effects of b-blocker therapy unique to heart failure with reduced left ventricular ejection fraction
The reduced expression of Gi in HFREF patients treated with b-blockers could be beneficial, because Gi is upregulated in HFREF patients with a dilated hypocontractile LV and contributes to the blunted inotropic response to adrenergic stimulation observed in these patients. 37, 38 Desmin phosphorylation responded differently to b-blocker therapy with increased phosphorylation in HFNEF and decreased phosphorylation in HFREF. Most previous studies on myofilamentary proteins looked at desmin expression and not at desmin phosphorylation. Desmin loss has been observed in ischaemic cardiomyopathy, 39 disrupted desmin in doxorubicininduced cardiotoxicity, 40 and desmin accumulation in restrictive cardiomyopathy. 41 Only one study reported on desmin phosphorylation and linked desmin phosphorylation to myofibrillar disarray in cardiomyopathic hamster hearts. 42 Based on this study, the reduced desmin phosphorylation in bþ HFREF could be beneficial, as it would limit myofibrillar disarray in HFREF hearts.
Limitations
Patient recruitment of the present study was based on referral for diagnostic endomyocardial biopsy procurement. This resulted in a cross-sectional, non-randomized study design. Ethical restrictions only allowed for diagnostic biopsy procurement. This prevented a serial, randomized study design because follow-up biopsies would no longer serve diagnostic purposes. The cross-sectional, non-randomized study design could cause untreated patients to systematically differ from treated patients because of the presence of certain comorbidities for which b-blockers were contraindicated. Such comorbidities, which could have significantly confounded the study results, were however unlikely. Failure to use b-blockers in the b2 HFREF group resulted mainly from the referring physician non-adhering to current guidelines as the majority of these patients (14/17) were started on b-blocker therapy during the same hospitalization. Furthermore, b-blockers were used in the bþ HFNEF group for control of arterial hypertension (14/16) and/or previous atrial tachyarrhythmias (4/16). Prevalence of arterial hypertension was, however, similar in the bþ HFNEF and b2 HFNEF groups ( Table 1 ) and, at the time of study, all patients were in regular sinus rhythm. The comparable LVEF in the b2 HFREF and bþ HFREF groups probably also resulted from patient recruitment based on referral for diagnostic endomyocardial biopsy procurement. This recruitment procedure introduced a bias consisting of more frequent referral for endomyocardial biopsy procurement in patients with a poor functional response to b-blocker therapy.
Conclusions
Myocardial effects associated with b-blocker therapy are either shared by HFNEF and HFREF groups, unique to HFNEF or unique to HFREF. 
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